Local biotech invests in erectile dysfunction drug

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

The company – which specializes in repurposing drugs already approved for other purposes – has signed a letter of intent to license a sublingual formation for drugs used to treat erectile dysfunction. Sublingual formations (which allow drugs to be dissolved under the tongue) absorb more quickly and therefore take effect sooner.

"We expect to move this product through pivotal trials and through regulatory approval over the next year and intend to begin marketing within two years," said Pacific Therapeutics CEO Douglas Unwin.

"We expect to complete the license in the first quarter of 2013, and move rapidly to the late-stage clinical trials and marketing."

In 2006, the market for drugs for treating erectile dysfunction exceeded $3 billion, the company said.

Pacific Therapeutics has two other drugs in the pipeline, both of which are for the treatment of scarring of human tissue.

Its lead product, PTL-202, is a combination of drugs being tested for efficacy in treating idiopathic pulmonary fibrosis, a progressive scarring of the lungs. The drug is already approved by the Food and Drug Administration in the U.S. and is currently in stage one of clinical trials.

nbennett@biv.com

@nbennett_biv

comments powered by Disqus

Also Read

More From Innovation

As Vancouver’s Westport Innovations (NASDAQ:WPRT) cuts jobs and salaries, the CEO of the natural gas engine manufacturer is hoping for growth in the coming year ...

Read Article

BioLytical Laboratories, the Richmond biotech best known for its 60-second HIV test, has developed ...

Read Article

As Toronto TV production companies are partnering with digital platform services, local digital producers still struggle to score a runaway success 

Read Article

Just US$1 billion in venture capital funding was invested in Canada last year compared with $US33.1 billion in the U.S. 

Read Article

Sixty million beacon devices are expected to ship by 2019 as startups and corporations rush to service emerging market 

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×